Valerio Therapeutics (XPAR:ALVIO) EV-to-EBIT : -0.96 (As of May. 21, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Valerio Therapeutics's Enterprise Value is €19.30 Mil. Valerio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-20.19 Mil. Therefore, Valerio Therapeutics's EV-to-EBIT for today is -0.96.

The historical rank and industry rank for Valerio Therapeutics's EV-to-EBIT or its related term are showing as below:

XPAR:ALVIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -79.35 Med: -3.27 Max: 18
Current: -0.96

During the past 13 years, the highest EV-to-EBIT of Valerio Therapeutics was 18.00. The lowest was -79.35. And the median was -3.27.

XPAR:ALVIO's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.09 vs XPAR:ALVIO: -0.96

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Valerio Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was €27.59 Mil. Valerio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-20.19 Mil. Valerio Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -73.17%.

Valerio Therapeutics EV-to-EBIT Historical Data

The historical data trend for Valerio Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics EV-to-EBIT Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-1.05

15.60

-6.12

-0.65

-1.37

Valerio Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-6.12	-	-0.65	-	-1.37

Competitive Comparison of Valerio Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Valerio Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's EV-to-EBIT falls into.

Valerio Therapeutics EV-to-EBIT Calculation

Valerio Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	19.304	/	-20.187
	=	-0.96

Valerio Therapeutics's current Enterprise Value is €19.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-20.19 Mil.

Valerio Therapeutics (XPAR:ALVIO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Valerio Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-20.187	/	27.58934
	=	-73.17 %

Valerio Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was €27.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-20.19 Mil.

Valerio Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (XPAR:ALVIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

C4X:Germany

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (XPAR:ALVIO) Headlines

No Headlines